Windsor John A, Barreto Savio George
HBP/Upper GI Unit, Department of General Surgery, Auckland City Hospital, Auckland, New Zealand;; Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Hepatobiliary and Oesophagogastric Unit, Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia.
J Gastrointest Oncol. 2017 Feb;8(1):189-193. doi: 10.21037/jgo.2016.12.06.
Pancreatic ductal adenocarcinoma (PDAC) is traditionally treated by a surgery-first approach. The development and adoption of the concept of borderline resectable PDAC, which extends the role of surgery, is based on the proposition that neoadjuvant therapy (NAT) will increase the resection rate, margin negative rate and overall survival. There are a number of issues with this concept and a critical review of these suggests that it is based on limited foundations and likely has a limited future.
胰腺导管腺癌（PDAC）传统上采用手术优先的治疗方法。可切除边缘PDAC概念的发展和应用扩展了手术的作用，其基于新辅助治疗（NAT）将提高切除率、切缘阴性率和总生存率这一观点。这一概念存在诸多问题，对这些问题进行批判性审视表明，它的基础有限，未来可能也很有限。
